Cargando…
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
Background: In metastatic breast cancer (MBC) patients, no biomarker predicting benefit to a bevacizumab-containing therapy has been established yet. MicroRNAs (miRNAs) are involved in angiogenesis and treatment resistance and therefore could be of predictive value. Methods: Profiling of 754 miRNAs...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355487/ https://www.ncbi.nlm.nih.gov/pubmed/32492882 http://dx.doi.org/10.3390/jcm9061663 |
_version_ | 1783558286873722880 |
---|---|
author | Rinnerthaler, Gabriel Gampenrieder, Simon Peter Hackl, Hubert Steiner, Markus Monzo-Fuentes, Claudia Melchardt, Thomas Magnes, Teresa Huemer, Florian Westphal, Theresa Hufnagl, Clemens Hauser-Kronberger, Cornelia Egle, Alexander Greil, Richard |
author_facet | Rinnerthaler, Gabriel Gampenrieder, Simon Peter Hackl, Hubert Steiner, Markus Monzo-Fuentes, Claudia Melchardt, Thomas Magnes, Teresa Huemer, Florian Westphal, Theresa Hufnagl, Clemens Hauser-Kronberger, Cornelia Egle, Alexander Greil, Richard |
author_sort | Rinnerthaler, Gabriel |
collection | PubMed |
description | Background: In metastatic breast cancer (MBC) patients, no biomarker predicting benefit to a bevacizumab-containing therapy has been established yet. MicroRNAs (miRNAs) are involved in angiogenesis and treatment resistance and therefore could be of predictive value. Methods: Profiling of 754 miRNAs was performed in tumor samples of 58 MBC patients treated with a bevacizumab-containing first-line regimen (learning set). Based on progression-free survival (PFS), patients were divided into responders (R) and non-responders (NR). Differentially expressed miRNAs between R and NR were analyzed in a cohort of 57 patients treated with first-line chemotherapy without bevacizumab (control set), to exclude miRNAs providing prognostic information. MiRNA candidates significantly associated with PFS in multivariate analysis were further validated in tumor samples of 203 patients treated within the phase III trial TANIA randomizing between chemotherapy either alone or with bevacizumab after progression on first-line bevacizumab. Results: Low expression of miR-20a-5p (multivariate p = 0.035) and miR-21-5p (multivariate p = 0.004) were significantly associated with longer PFS in the learning set, but not in the control set. In samples from the TANIA trial, low expression of miR-20a-5p was also significantly associated with longer PFS (hazard ration (HR) 0.60; 95%-CI 0.37–0.89; p = 0.012) and longer overall survival (OS; HR 0.54; 95%-CI 0.32–0.83; p = 0.007) in the bevacizumab arm but not in the chemotherapy-only arm (PFS: HR 0.73, p = 0.119; OS: HR 1.01; p = 0.964). For miR-21-5p no significant association with PFS or OS in both treatment arms was observed. Conclusion: MiR-20a-5p expression in breast cancer tissue was predictive for a greater benefit from bevacizumab-containing therapy in two independent cohorts. |
format | Online Article Text |
id | pubmed-7355487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73554872020-07-23 Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial Rinnerthaler, Gabriel Gampenrieder, Simon Peter Hackl, Hubert Steiner, Markus Monzo-Fuentes, Claudia Melchardt, Thomas Magnes, Teresa Huemer, Florian Westphal, Theresa Hufnagl, Clemens Hauser-Kronberger, Cornelia Egle, Alexander Greil, Richard J Clin Med Article Background: In metastatic breast cancer (MBC) patients, no biomarker predicting benefit to a bevacizumab-containing therapy has been established yet. MicroRNAs (miRNAs) are involved in angiogenesis and treatment resistance and therefore could be of predictive value. Methods: Profiling of 754 miRNAs was performed in tumor samples of 58 MBC patients treated with a bevacizumab-containing first-line regimen (learning set). Based on progression-free survival (PFS), patients were divided into responders (R) and non-responders (NR). Differentially expressed miRNAs between R and NR were analyzed in a cohort of 57 patients treated with first-line chemotherapy without bevacizumab (control set), to exclude miRNAs providing prognostic information. MiRNA candidates significantly associated with PFS in multivariate analysis were further validated in tumor samples of 203 patients treated within the phase III trial TANIA randomizing between chemotherapy either alone or with bevacizumab after progression on first-line bevacizumab. Results: Low expression of miR-20a-5p (multivariate p = 0.035) and miR-21-5p (multivariate p = 0.004) were significantly associated with longer PFS in the learning set, but not in the control set. In samples from the TANIA trial, low expression of miR-20a-5p was also significantly associated with longer PFS (hazard ration (HR) 0.60; 95%-CI 0.37–0.89; p = 0.012) and longer overall survival (OS; HR 0.54; 95%-CI 0.32–0.83; p = 0.007) in the bevacizumab arm but not in the chemotherapy-only arm (PFS: HR 0.73, p = 0.119; OS: HR 1.01; p = 0.964). For miR-21-5p no significant association with PFS or OS in both treatment arms was observed. Conclusion: MiR-20a-5p expression in breast cancer tissue was predictive for a greater benefit from bevacizumab-containing therapy in two independent cohorts. MDPI 2020-06-01 /pmc/articles/PMC7355487/ /pubmed/32492882 http://dx.doi.org/10.3390/jcm9061663 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rinnerthaler, Gabriel Gampenrieder, Simon Peter Hackl, Hubert Steiner, Markus Monzo-Fuentes, Claudia Melchardt, Thomas Magnes, Teresa Huemer, Florian Westphal, Theresa Hufnagl, Clemens Hauser-Kronberger, Cornelia Egle, Alexander Greil, Richard Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial |
title | Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial |
title_full | Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial |
title_fullStr | Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial |
title_full_unstemmed | Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial |
title_short | Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial |
title_sort | low expression of mir-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the tania phase iii trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355487/ https://www.ncbi.nlm.nih.gov/pubmed/32492882 http://dx.doi.org/10.3390/jcm9061663 |
work_keys_str_mv | AT rinnerthalergabriel lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT gampenriedersimonpeter lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT hacklhubert lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT steinermarkus lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT monzofuentesclaudia lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT melchardtthomas lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT magnesteresa lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT huemerflorian lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT westphaltheresa lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT hufnaglclemens lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT hauserkronbergercornelia lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT eglealexander lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial AT greilrichard lowexpressionofmir20a5ppredictsbenefittobevacizumabinmetastaticbreastcancerpatientstreatedwithinthetaniaphaseiiitrial |